Re-evaluation of nondiagnostic biopsies of suspected low-grade glioma using isocitrate dehydrogenase 1 mutation immunohistochemistry.
作者信息
Anderson Mark D, Abel Ty W, Moots Paul L
出版信息
Neuro Oncol. 2013 Jul;15(7):811-3. doi: 10.1093/neuonc/not063. Epub 2013 Jun 4.
Abstract
摘要
相似文献
1
Re-evaluation of nondiagnostic biopsies of suspected low-grade glioma using isocitrate dehydrogenase 1 mutation immunohistochemistry.使用异柠檬酸脱氢酶1突变免疫组织化学对疑似低级别胶质瘤的非诊断性活检进行重新评估。
Neuro Oncol. 2013 Jul;15(7):811-3. doi: 10.1093/neuonc/not063. Epub 2013 Jun 4.
2
Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing.免疫组织化学和 DNA 测序检测脑肿瘤 IDH1 基因突变的对比研究。
Neuro Oncol. 2013 Jun;15(6):718-26. doi: 10.1093/neuonc/not015. Epub 2013 Mar 13.
3
Avoiding New Biopsies by Identification of IDH1 and TERT Promoter Mutation in Nondiagnostic Biopsies From Glioma Patients.避免对脑胶质瘤患者非诊断性活检组织进行 IDH1 和 TERT 启动子突变检测。
Neurosurgery. 2020 Sep 15;87(4):E513-E519. doi: 10.1093/neuros/nyaa025.
4
Imaging prediction of isocitrate dehydrogenase (IDH) mutation in patients with glioma: a systemic review and meta-analysis.影像学预测脑胶质瘤患者异柠檬酸脱氢酶（IDH）突变：系统评价和荟萃分析。
Eur Radiol. 2019 Feb;29(2):745-758. doi: 10.1007/s00330-018-5608-7. Epub 2018 Jul 12.
5
Metabolism: reprogramming metabolic flux in glioma.代谢：胶质瘤中代谢通量的重编程
Nat Rev Cancer. 2014 Nov;14(11):706-7. doi: 10.1038/nrc3840. Epub 2014 Oct 6.
6
Metabolism, gliomas, and IDH1.代谢、胶质瘤与异柠檬酸脱氢酶1
N Engl J Med. 2010 Mar 25;362(12):1144-5. doi: 10.1056/NEJMcibr0912922.
7
Prediction of IDH Status Through MRI Features and Enlightened Reflection on the Delineation of Target Volume in Low-Grade Gliomas.通过 MRI 特征预测 IDH 状态，并对低级别胶质瘤靶区勾画进行深入思考。
Technol Cancer Res Treat. 2019 Jan 1;18:1533033819877167. doi: 10.1177/1533033819877167.
8
Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors.免疫组织化学检测 IDH1 突变、p53 和连接蛋白作为神经胶质瘤的预后因素。
J Neurooncol. 2012 Jul;108(3):361-73. doi: 10.1007/s11060-012-0837-0. Epub 2012 Mar 7.
9
Interlaboratory comparison of IDH mutation detection.IDH 突变检测的实验室间比较。
J Neurooncol. 2013 Apr;112(2):173-8. doi: 10.1007/s11060-013-1056-z. Epub 2013 Jan 29.
10
IDH-mutant brainstem gliomas in adolescent and young adult patients: Report of three cases and review of the literature.青少年和年轻成人患者的 IDH 突变型脑干胶质瘤：三例报告及文献复习。
Brain Pathol. 2021 Jul;31(4):e12959. doi: 10.1111/bpa.12959. Epub 2021 May 7.
引用本文的文献
1
A Simple Panel of IDH1 and P53 in Differential Diagnosis Between Low-Grade Astrocytoma and Reactive Gliosis.用于低级别星形细胞瘤与反应性胶质增生鉴别诊断的IDH1和P53简易检测组合
Clin Pathol. 2021 Feb 11;14:2632010X20986168. doi: 10.1177/2632010X20986168. eCollection 2021 Jan-Dec.
2
Percutaneous CT-guided needle biopsies of musculoskeletal tumors: a 5-year analysis of non-diagnostic biopsies.经皮CT引导下肌肉骨骼肿瘤穿刺活检：对非诊断性活检的5年分析
Skeletal Radiol. 2015 Dec;44(12):1795-803. doi: 10.1007/s00256-015-2235-0. Epub 2015 Sep 4.
本文引用的文献
1
Pyrosequencing of IDH1 and IDH2 mutations in brain tumors and non-neoplastic conditions.脑肿瘤和非肿瘤性疾病中异柠檬酸脱氢酶1（IDH1）和异柠檬酸脱氢酶2（IDH2）突变的焦磷酸测序
Diagn Mol Pathol. 2012 Dec;21(4):214-20. doi: 10.1097/PDM.0b013e31825d802b.
2
Molecular pathogenesis of IDH mutations in gliomas.胶质瘤中 IDH 突变的分子发病机制。
Brain Tumor Pathol. 2012 Jul;29(3):131-9. doi: 10.1007/s10014-012-0090-4. Epub 2012 Mar 8.
3
One hundred and one dysembryoplastic neuroepithelial tumors: an adult epilepsy series with immunohistochemical, molecular genetic, and clinical correlations and a review of the literature.101 例胚胎发育不良性神经上皮肿瘤：一项具有免疫组织化学、分子遗传学和临床相关性的成人癫痫系列研究，并对文献进行回顾。
J Neuropathol Exp Neurol. 2011 Oct;70(10):859-78. doi: 10.1097/NEN.0b013e3182302475.
4
IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors.异柠檬酸脱氢酶 1 和 2 突变、免疫组织化学及一系列脑肿瘤中的关联。
J Neurooncol. 2011 Nov;105(2):345-57. doi: 10.1007/s11060-011-0596-3. Epub 2011 Jun 4.
5
High-throughput immunohistochemical profiling of primary brain tumors and non-neoplastic systemic organs with a specific antibody against the mutant isocitrate dehydrogenase 1 R132H protein.高通量免疫组化分析原发性脑肿瘤和非肿瘤性全身器官，使用特异性抗体针对突变型异柠檬酸脱氢酶 1 R132H 蛋白。
Brain Tumor Pathol. 2011 Apr;28(2):107-14. doi: 10.1007/s10014-010-0016-y. Epub 2011 Jan 7.
6
Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes.突变 IDH1 抗体在鉴别弥漫性胶质瘤与非肿瘤性中枢神经系统病变及治疗相关性改变中的应用。
Am J Surg Pathol. 2010 Aug;34(8):1199-204. doi: 10.1097/PAS.0b013e3181e7740d.
7
Mutant metabolic enzymes are at the origin of gliomas.突变代谢酶是神经胶质瘤的起源。
Cancer Res. 2009 Dec 15;69(24):9157-9. doi: 10.1158/0008-5472.CAN-09-2650.
8
Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues.异柠檬酸脱氢酶1/2（IDH1/2）突变分析在福尔马林固定、石蜡包埋胶质瘤组织常规临床检测中的诊断应用
J Neuropathol Exp Neurol. 2009 Dec;68(12):1319-25. doi: 10.1097/NEN.0b013e3181c391be.
Zotero 插件